Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent 120 Million Private Placement
| ELYMDelisted Stock | USD 3.09 0.06 1.90% |
About 60% of Eliem Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Eliem Therapeutics suggests that many traders are alarmed regarding Eliem Therapeutics' prospects. Eliem Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Eliem Therapeutics. Many technical investors use Eliem Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Eliem |
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately 210 million of cash and cash equivalents, including 120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT119, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia Co
Read at finance.yahoo.com
 |
Eliem Therapeutics Fundamental Analysis
We analyze Eliem Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Eliem Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Eliem Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eliem Therapeutics stock to make a market-neutral strategy. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with similar companies.
Peers
Eliem Therapeutics Related Equities
| CSBR | Champions Oncology | 12.09 | ||||
| PHVS | Pharvaris | 6.07 | ||||
| PMVP | Pmv Pharmaceuticals | 3.82 | ||||
| ACRV | Acrivon Therapeutics, | 3.63 | ||||
| STTK | Shattuck Labs | 2.31 | ||||
| AVTE | Aerovate Therapeutics | 1.54 | ||||
| MOLN | Molecular Partners | 2.13 | ||||
| ADAG | Adagene | 2.36 | ||||
| HCWB | HCW Biologics | 2.50 | ||||
| ANTX | AN2 Therapeutics | 2.58 | ||||
| MNOV | MediciNova | 3.98 | ||||
| IPSC | Century Therapeutics | 4.08 | ||||
| PEPG | PepGen | 5.84 | ||||
| RZLT | Rezolute | 7.47 | ||||
| ANEB | Anebulo Pharmaceuticals | 10.83 |
Check out Eliem Therapeutics Hype Analysis, Eliem Therapeutics Correlation and Eliem Therapeutics Performance. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |